Advertisement
Advertisement
AUTL
Autolus Therapeutics plc - ADR
2.11
USDSponsored
+0.11
+5.50%
Aug 07, 15:58 UTC -4
Closed
After-Market
2.12
+0.01
+0.24%
AUTL Earnings Reports
Positive Surprise Ratio
AUTL beat 14 of 29 last estimates.
48%
Next Report
Tomorrow
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$30.34M
/-$0.22
Implied change from Q1 26 (Revenue/ EPS)
+15.71%
/-18.52%
Implied change from Q2 25 (Revenue/ EPS)
+44.99%
/+22.22%
Autolus Therapeutics plc - ADR earnings per share and revenue
On May 14, 2026, AUTL reported earnings of -0.27 USD per share (EPS) for Q1 26, missing the estimate of -0.26 USD, resulting in a -2.94% surprise. Revenue reached 26.22 million, compared to an expected 26.68 million, with a -1.75% difference. The market reacted with a -7.02% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.22 USD, with revenue projected to reach 30.34 million USD, implying an decrease of -18.52% EPS, and increase of 15.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Autolus Therapeutics plc - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Autolus Therapeutics plc - ADR reported EPS of -$0.27, missing estimates by -2.94%, and revenue of $26.22M, -1.75% below expectations.
How did the market react to Autolus Therapeutics plc - ADR's Q1 2026 earnings?
The stock price moved down -7.02%, changed from $1.71 before the earnings release to $1.59 the day after.
When is Autolus Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Autolus Therapeutics plc - ADR's next earnings report?
Based on 6
analysts, Autolus Therapeutics plc - ADR is expected to report EPS of -$0.22 and revenue of $30.34M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement